Concepedia

Arnon P. Kater

AP

Statistics

Publications

154

Citations

11K

H-Index

52

Active since

1999

Affiliations

University of Amsterdam(Current)

Amsterdam University Medical Centers

Amsterdam UMC Location University of Amsterdam

Rigshospitalet

Peter MacCallum Cancer Centre

Arnon P. Kater is an author at University of Amsterdam specializing in oncology, chronic lymphocytic leukemia therapy, and medicine.

ORCID

Publications per year

1999–2025

154

Publications

154

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

, , +13

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

John C. Byrd, Peter Hillmen, Paolo Ghia et al. · Journal of Clinical Oncology · 2021 · 635 citations · Full text

, , +10

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology · 2020 · 568 citations · Full text

, , +14

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Michael Wang, Simon Rule, Pier Luigi Zinzani et al. · The Lancet · 2017 · 448 citations · Full text

, , +11

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Arnon P. Kater, John F. Seymour, Peter Hillmen et al. · Journal of Clinical Oncology · 2018 · 301 citations · Full text

, , +16

1–5 of 154